Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance

Hepatology

Volumn 49, Issue 1, 2009, Pages 87-96

  Singh, Rajat ^a   Wang, Yongjun ^a   Xiang, Youqing ^a   Tanaka, Kathryn E ^a   Gaarde, William A ^b   Czaja, Mark J ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; BIM PROTEIN; GLUCOSE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE 1; APOPTOSIS REGULATORY PROTEIN; BAX PROTEIN, MOUSE; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 9; ONCOPROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATTY LIVER; GENE EXPRESSION; GENE FUNCTION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER PROTECTION; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; FAT INTAKE; LIVER; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; DIETARY FATS; FATTY LIVER; INSULIN RESISTANCE; LIVER; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS;

EID: 58949093454     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22578     Document Type: Article

References (37)

1. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863-869.
2. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
3. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
4. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420: 333-336.
5. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004;10:1128-1132.
6. Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. HEPATOLOGY 2006;43:163-172.
7. Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil GS. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A 2006;103:10741-10746.
8. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
9. Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jundependent cell proliferation. Mol Cell 2004;15:713-725.
10. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005;280:9887-9894.
11. Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006;131:165-178.
12. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, Flavell RA. Defective T cell differentiation in the absence of Jnk1. Science 1998;282: 2092-2095.
13. Yang DD, Conze D, Whitmarsh AJ, Barrett T, Davis RJ, Rincon M, et al. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998;9:575-585.
14. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999;286:1735-1738.
15. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM, et al. 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 1997;272: 11994-12000.
16. D'Ambra R, Surana M, Efrat S, Starr RG, Fleischer N. Regulation of insulin secretion from beta-cell lines derived from transgenic mice insulinomas resembles that of normal beta-cells. Endocrinology 1990;126: 2815-2822.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
18. Wang Y, Singh R, Lefkowitch JH, Rigoli RM, Czaja MJ. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem 2006;281: 15258-15267.
19. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006;281:12093-12101.
20. EL causing its phosphorylation and turnover. J Biol Chem 2004;279:8837-8847.
21. Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J, et al. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 2002;277:43730-43734.
22. Baskin-Bey ES, Gores GJ. Death by association: BH3 domain-only proteins and liver injury. Am J Physiol Gastrointest Liver Physiol 2005;289: G987-G990.
23. Corazza N, Jakob S, Schaer C, Frese S, Keogh A, Stroka D, et al. TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest 2006;116: 2493-2499.
24. 2-terminal kinase in TNFα- and Fas-mediated apoptosis in hepatocytes. FASEB J 2004; 18:720-722.
25. Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, Westwick JK, et al. JNK mediates hepatic ischemia reperfusion injury. J Hepatol 2005;42: 850-859.
26. 2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol Cell Biol 2003;23:3052-3066.
27. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004;40: 47-51.
28. Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A 2006; 103:16454-16459.
29. Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W, et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 2007;6:386-397.
30. Bogoyevitch MA, Kobe B. Uses for JNK: The many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 2006;70:1061-1095.
31. Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, et al. Pharmacokinetics of a tumor necrosis factor-α phosphorothioate 2′- O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003;31:1419-1428.
32. Fishman S, Muzumdar RH, Atzmon G, Ma X, Yang X, Einstein FH, et al. Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo. FASEB J 2007;21:53-60.
33. EL-a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 2008;29:544-551.
34. Putcha GV, Moulder KL, Golden JP, Bouillet P, Adams JA, Strasser A, et al. Induction of BIM, a proapoptotic BH3-only BCL-2 family member, is critical for neuronal apoptosis. Neuron 2001;29:615-628.
35. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 2001;29: 629-643.
36. EL apoptotic function. J Biol Chem 2006; 281:813-823.
37. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-480.